Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Depamal Plus
- Development stage
- Preclinical
- Lead developer
- Provident Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Depamal Plus is a fixed-dose combination (FDC) small molecule therapy developed and marketed by Provident Pharmaceuticals for the management of type 2 diabetes mellitus. It consists of dapagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, and metformin, a biguanide. Dapagliflozin works by inhibiting SGLT2 in the proximal renal tubules, thereby reducing renal glucose reabsorption and increasing urinary glucose excretion. Metformin exerts its effects by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. Metformin's molecular mechanism involves the activation of the AMP-activated protein kinase (AMPK) pathway and the inhibition of mitochondrial complex I in the respiratory chain. Depamal Plus is intended to provide glycemic control through these complementary pathways and is listed as an upcoming product in the Greek pharmaceutical market.
- Brand names
- Depamal Plus
- Other names
- dapagliflozin + metformin
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on Depamal Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Depamal Plus.